![Image: [image credit]](/wp-content/themes/yootheme/cache/e1/dreamstime_xxl_146315200-scaled-e1dd7dd4.webp)
Few corners of healthcare are under as much political and commercial pressure as the pharmacy benefit manager (PBM) sector. Long accused of obscuring true drug costs behind layers of contracts, rebates, and spread pricing, PBMs are now facing unprecedented scrutiny from lawmakers, employer groups, and regulators—and the data war is central to the fight.
At stake is not just how drugs are priced, but how data is accessed, shared, and used across the pharmaceutical supply chain. For healthcare IT vendors, health plans, and analytics firms, the growing demand for transparency presents both a business opportunity and a complex regulatory challenge.
Legislative Momentum, Political Uncertainty
While end-of-year PBM reform legislation failed in December 2024, the new Congress has reignited debate. Multiple bills—some bipartisan—aim to dismantle the current PBM revenue model, with provisions to:
- De-link PBM compensation from drug prices
- Ban spread pricing in Medicaid and commercial plans
- Require pass-through of rebates to employers and patients
- Mandate public disclosure of negotiated prices and formulary placement criteria
A coalition of employers, independent pharmacists, and alternative PBMs, including Blue Shield of California and Transcarent, sent a letter to Congress in February urging passage of comprehensive PBM reform, stating, “PBMs have persistently resisted transparency, and it’s time for Congress to act.”
Surprisingly, even PhRMA, the powerful pharmaceutical industry lobbying group, has backed some transparency measures—partly to redirect blame for high drug prices.
Data Lock-In and the Infrastructure Barrier
One of the biggest barriers to reform is infrastructure. Most PBM platforms were never designed for transparency. Instead, they’re built for claims adjudication, rebate optimization, and proprietary formulary management—often with minimal interoperability or external auditability.
“These systems aren’t black boxes by accident. They were designed that way to protect margin,” said Lisa O’Leary, VP of compliance strategy at Navitus Health Solutions, an alternative PBM that operates on a transparent pass-through model.
Unlocking that data will require major system overhauls. From API deployment to payer integrations, IT leaders across the drug supply chain will need to build new pipelines for claims data, rebate flows, and pricing benchmarks.
Companies like MedicineMarketRx and Civica Rx are attempting to bypass the PBM middle layer entirely by providing direct-to-employer contracting platforms and nonprofit generics, respectively—but these models are not yet mainstream.
Regulatory Push Meets AI Complexity
As new AI tools emerge to forecast pharmacy spend, recommend formulary changes, or detect fraud, policymakers are asking whether these algorithms are being transparently applied—or whether they’re reinforcing opaque contracting patterns.
Earlier this month, the Federal Trade Commission (FTC) signaled it would expand its investigation into PBM practices to include AI-driven rebate models and automated formulary decisions. The agency is reportedly exploring whether certain AI applications are being used to steer patients toward higher-margin drugs under the guise of clinical optimization.
“We need to ensure that machine learning in pharmacy doesn’t become the next front of anti-competitive behavior,” said FTC Chair Lina Khan at a recent Brookings Institution event.
Employer Coalitions Driving Change
Frustrated by rising drug costs and unclear rebate structures, employer groups are pushing for control over their own pharmacy data. The Catalyst for Payment Reform and the Purchaser Business Group on Health are advocating for new federal rules requiring PBMs to share claims-level data with plan sponsors in near real-time.
Several Fortune 100 employers are now negotiating carve-outs in PBM contracts to require transparent reporting or to allow independent data warehousing and analytics through third-party vendors like Milliman or Truveris.
“We’re not waiting for Washington,” said Sarah Kline, head of benefits at a major aerospace firm. “We’re writing data transparency into every contract, and if a PBM won’t comply, we’ll walk.”
The Outlook: Fragmentation or Standardization?
The PBM space is entering a defining moment. If Congress passes reform by late 2025, it could create new requirements for data interoperability, AI accountability, and real-time transparency. If not, expect a patchwork of employer-driven standards, state-level mandates, and voluntary reform from alternative PBMs trying to capture market share.
Healthcare IT vendors and payers must prepare now by assessing whether their systems can support greater visibility into drug pricing and rebate mechanics—and whether they are aligned with a future of radical transparency or stuck in legacy opacity.
The future of PBM reform is ultimately a data problem. And the healthcare organizations that solve it first may win not just the contract—but the trust of a deeply skeptical market.
Sources: